



## Publication of a Transparency Notification Received from Alychlo NV

**Liege, Belgium, 10 July 2020 – 17:45 CEST** – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of transparency from Alychlo NV, having its registered seat located at Lembergsesteenweg 19, 9820 Merelbeke, on 9 July 2020.

Alychlo NV has notified Mithra that it has dropped below the 15% statutory threshold on 23 June 2020, following the capital increase by means of a private placement launched on 18 June 2020. Alychlo NV now holds 14,93% (6,354,445 shares) of the 42,554,297 shares currently outstanding. Previously, Alychlo NV held 15,84% of the 39,133,245 shares outstanding.

The detailed transparency notifications are available on the [Investors website](https://investors.mithra.com) of Mithra ([investors.mithra.com](https://investors.mithra.com)). An updated overview of the Mithra's large shareholdings will be included in the corporate governance charter of Mithra, which will be made available on its website.

\*\*\*\*\*

### For more information, please contact:

**Alexandra Deschner (IRO)** : +32 490 58 35 23 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)  
**Maud Vanderthommen (Press)** : +32 473 58 61 04- [press@mithra.com](mailto:press@mithra.com)

### About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. [www.mithra.com](https://www.mithra.com)

### Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

---

Subscribe to our mailing list on [investors.mithra.com](https://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)